Author Archives: Sara Guariglia

DTx Pharma Receives NIH Funding to Advance RNA-based Therapies for CMT

The National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health (NIH), has awarded DTx Pharma a funding grant to advance development of promising new therapeutic candidates for Charcot-Marie-Tooth (CMT) type 1A (CMT1A) disease. The therapeutic candidates are specially designed RNA oligonucleotide…